Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2024-12-04 Board/Management Inform…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
AstraZeneca appoints Iskra Reic EVP International
Board/Management Information Classification · 99% confidence The document is a formal announcement released via RNS (Regulatory News Service) on December 4, 2024, detailing the appointment of a new Executive Vice President (Iskra Reic) and providing biographical details. This directly relates to a change in senior management/board structure. The definition for Board/Management Information (MANG) covers 'Announcement of changes in the company's board of directors or senior management.' Although it is distributed via RNS, the specific content is management change, making MANG the most precise classification over the general RNS fallback.
2024-12-04 English
BLOCK LISTING INTERIM REVIEW
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content includes a block listing six monthly return related to share option plans, covering the period from June 1, 2024, to November 30, 2024. The document is relatively short (3599 characters) and primarily provides regulatory information about share schemes and allotments. It does not contain comprehensive financial statements or detailed financial analysis typical of interim or annual reports. It is not an earnings release, call transcript, or management report. The document is a regulatory filing providing specific compliance information about share schemes and block listings, which fits best under the Regulatory Filings (RNS) category as a general regulatory announcement that does not fit other specific categories.
2024-12-02 English
TOTAL VOTING RIGHTS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the total voting rights as of a specific date (30 November 2024) and provides information relevant to the UK Financial Conduct Authority's Disclosure and Transparency Rules. The document is relatively short (3185 characters) and primarily serves as a notification of voting rights rather than a full report or detailed financial disclosure. It does not contain financial statements, management discussion, or detailed analysis. This type of filing is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement that does not fit into more specific categories like Annual Report, Interim Report, or Voting Results. It is not a Declaration of Voting Results (DVA) since it does not report shareholder vote outcomes but rather the total voting rights figure for transparency purposes.
2024-12-02 English
Block listing Interim Review
Share Issue/Capital Change Classification · 99% confidence The document is explicitly labeled as an 'RNS Number' and contains a 'BLOCK LISTING SIX MONTHLY RETURN' for AstraZeneca PLC, covering the period from June 1, 2024, to November 30, 2024. This type of filing, which reports on the status of unallotted securities under employee share schemes, is a specific regulatory disclosure. While it is a formal report, the presence of the RNS header and the nature of the content (a structured return to a regulatory body, likely the LSE) strongly suggests it falls under general regulatory announcements. Since there is no specific code for a 'Block Listing Return' and it is not an earnings release (ER), annual report (10-K), or interim report (IR), the most appropriate classification is the general regulatory filing category, RNS, as it is distributed via the RNS service.
2024-12-02 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly states it is providing information via 'RNS, the news service of the London Stock Exchange'. The content details the total number of voting rights and issued share capital as of a specific date (30 November 2024), which is a mandatory disclosure under the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of regulatory update regarding voting rights and capital structure is a specific regulatory announcement. While it relates to capital, it is not a financing activity (CAP) or a share repurchase (POS), but rather a mandatory disclosure of existing capital structure for voting purposes. Since it is a specific regulatory announcement that doesn't fit perfectly into the other specific categories (like DVA for voting *results*), and it is distributed via RNS, the most appropriate classification is RNS, which serves as the general regulatory filing category for such disclosures not covered elsewhere, or potentially DVA if the context was strictly about voting rights calculation, but RNS is safer for general transparency rule updates. Given the options, RNS (Regulatory Filings) is the best fit for a standard FCA transparency rule disclosure.
2024-12-02 English
TRUQAP IMPROVED RPFS IN ADVANCED PROSTATE CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, submitted to the SEC as a report of a foreign issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. It contains detailed clinical trial results for the drug Truqap in advanced prostate cancer, including statistical outcomes, trial design, and safety profile. The document is dated November 2024 and is over 11,000 characters long, indicating it is a substantive report rather than a brief announcement. Form 6-K filings typically serve as current reports for foreign issuers to disclose material information that is not included in their annual reports (20-F or 40-F). This document does not contain full annual financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not an earnings release, call transcript, or management report. The content focuses on clinical trial results and regulatory updates related to a pharmaceutical product, which is typical for a 6-K filing. Given the nature of the document as a current report of material information by a foreign issuer, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2024-11-25 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.